Vontobel Holding Ltd. Trims Holdings in Humana Inc. (NYSE:HUM)

Vontobel Holding Ltd. lowered its position in Humana Inc. (NYSE:HUM) by 28.7% during the first quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 1,547 shares of the insurance provider’s stock after selling 622 shares during the period. Vontobel Holding Ltd.’s holdings in Humana were worth $649,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other large investors have also modified their holdings of HUM. IndexIQ Advisors LLC boosted its holdings in shares of Humana by 12.3% in the 4th quarter. IndexIQ Advisors LLC now owns 7,880 shares of the insurance provider’s stock valued at $3,233,000 after acquiring an additional 865 shares during the last quarter. Charles Schwab Investment Management Inc. boosted its holdings in Humana by 0.4% in the fourth quarter. Charles Schwab Investment Management Inc. now owns 677,107 shares of the insurance provider’s stock valued at $277,797,000 after purchasing an additional 2,962 shares during the last quarter. ING Groep NV grew its position in Humana by 199.8% during the 4th quarter. ING Groep NV now owns 8,778 shares of the insurance provider’s stock worth $3,601,000 after purchasing an additional 5,850 shares during the period. ExodusPoint Capital Management LP raised its stake in shares of Humana by 135.4% during the 4th quarter. ExodusPoint Capital Management LP now owns 8,803 shares of the insurance provider’s stock valued at $3,612,000 after buying an additional 5,064 shares during the last quarter. Finally, Boston Partners lifted its holdings in shares of Humana by 1.4% in the 4th quarter. Boston Partners now owns 689,526 shares of the insurance provider’s stock valued at $282,892,000 after buying an additional 9,584 shares during the period. Institutional investors own 92.11% of the company’s stock.

In related news, insider Christopher H. Hunter sold 5,156 shares of Humana stock in a transaction that occurred on Thursday, April 29th. The stock was sold at an average price of $443.76, for a total transaction of $2,288,026.56. Following the transaction, the insider now owns 8,653 shares in the company, valued at $3,839,855.28. The sale was disclosed in a document filed with the SEC, which is accessible through this link. Also, insider Timothy Alan Wheatley sold 8,508 shares of the business’s stock in a transaction on Monday, May 3rd. The stock was sold at an average price of $450.59, for a total value of $3,833,619.72. Following the transaction, the insider now directly owns 11,494 shares in the company, valued at approximately $5,179,081.46. The disclosure for this sale can be found here. 0.40% of the stock is currently owned by corporate insiders.

Several brokerages recently weighed in on HUM. Mizuho lifted their price target on Humana from $462.00 to $480.00 and gave the company a “buy” rating in a research report on Thursday, April 29th. Wells Fargo & Company assumed coverage on shares of Humana in a report on Monday, May 24th. They set an “equal weight” rating and a $472.00 target price for the company. Citigroup Inc. 3% Minimum Coupon Principal Protected Based Upon Russell increased their price target on shares of Humana from $496.00 to $510.00 and gave the stock a “buy” rating in a report on Thursday, April 29th. Oppenheimer lifted their price objective on shares of Humana from $460.00 to $480.00 and gave the company an “outperform” rating in a report on Thursday, April 29th. Finally, Citigroup increased their target price on shares of Humana from $496.00 to $510.00 in a research note on Thursday, April 29th. One equities research analyst has rated the stock with a sell rating, four have given a hold rating and ten have assigned a buy rating to the company’s stock. The company currently has an average rating of “Buy” and a consensus target price of $469.00.

Shares of Humana stock opened at $420.96 on Friday. The firm has a market capitalization of $54.31 billion, a PE ratio of 14.97, a P/E/G ratio of 1.46 and a beta of 0.88. The firm’s 50 day moving average price is $437.99. Humana Inc. has a 12 month low of $365.06 and a 12 month high of $475.44. The company has a quick ratio of 1.67, a current ratio of 1.67 and a debt-to-equity ratio of 0.43.

Humana (NYSE:HUM) last issued its quarterly earnings results on Wednesday, April 28th. The insurance provider reported $7.67 EPS for the quarter, topping the Thomson Reuters’ consensus estimate of $7.21 by $0.46. Humana had a return on equity of 19.08% and a net margin of 4.72%. The firm had revenue of $20.67 billion during the quarter, compared to analysts’ expectations of $20.42 billion. During the same period in the previous year, the business earned $5.40 earnings per share. The firm’s revenue for the quarter was up 9.2% on a year-over-year basis. As a group, equities analysts forecast that Humana Inc. will post 21.64 EPS for the current fiscal year.

The firm also recently declared a quarterly dividend, which will be paid on Friday, July 30th. Investors of record on Wednesday, June 30th will be given a dividend of $0.70 per share. The ex-dividend date is Tuesday, June 29th. This represents a $2.80 dividend on an annualized basis and a yield of 0.67%. Humana’s payout ratio is presently 14.93%.

Humana Profile

Humana Inc, together with its subsidiaries, operates as a health and well-being company in the United States. It operates through Retail, Group and Specialty, and Healthcare Services segments. The company offers medical and supplemental benefit plans to individuals. It also has a contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits.

Read More: What are the most popular ETFs

Want to see what other hedge funds are holding HUM? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Humana Inc. (NYSE:HUM).

Institutional Ownership by Quarter for Humana (NYSE:HUM)

Receive News & Ratings for Humana Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Humana and related companies with MarketBeat.com's FREE daily email newsletter.